AHR and pancreatic ductal adenocarcinoma: [131] demonstrated that pharmacologic inhibition of aryl hydrocarbon receptor (AhR) in myeloid cells reduced pancreatic ductal adenocarcinoma growth and improved efficacy of immune checkpoint blockade, and increased intra-tumoral frequencies of IFNγ+CD8+ T cells.